Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission
] Objective To compare the efficacy of autologous and allogeneic peripheral blood hematopoietic stem cell transplantation (PB-HCT) for non-high-risk acute myeloid leukemia (AML) patients having achieved first complete remission (CR1). Methods A total of 73 patients with CR1 stage AML (non-high risk)...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Third Military Medical University
2020-09-01
|
| Series: | Di-san junyi daxue xuebao |
| Subjects: | |
| Online Access: | http://aammt.tmmu.edu.cn/Upload/rhtml/202005132.htm |
| _version_ | 1819227384196366336 |
|---|---|
| author | XIAO Han WANG Xin LUO Xiaohua XIAO Qing ZHANG Hongbin TANG Xiaoqiong LIU Lin |
| author_facet | XIAO Han WANG Xin LUO Xiaohua XIAO Qing ZHANG Hongbin TANG Xiaoqiong LIU Lin |
| author_sort | XIAO Han |
| collection | DOAJ |
| description | ] Objective To compare the efficacy of autologous and allogeneic peripheral blood hematopoietic stem cell transplantation (PB-HCT) for non-high-risk acute myeloid leukemia (AML) patients having achieved first complete remission (CR1). Methods A total of 73 patients with CR1 stage AML (non-high risk) who underwent PB-HCT in our department from January 2012 to June 2019 were enrolled in this study, and they were 49 patients receiving allogeneic PB-HCT and 24 getting autologous PB-HCT. The time of hematopoietic reconstruction, required transfusion volume, the number times of early infections, 1-year cumulative relapse incidence (RI) and non-relapse mortality (NRM), 1-year overall survival (OS) and leukemia-free survival (LFS) were compared between the 2 groups. Results There were no significant differences in hematopoietic reconstruction time, required transfusion volume and the number times of early infections between the 2 groups. As for the autologous PB-HCT group and allogeneic PB-HCT group, 1-year RI was 25.4% and 6.2% (P < 0.01); 1-year NRM was 0.0% and 8.3% (P=0.15); 1-year OS was 95.8% and 89.5% (P=0.80); and 1-year LFS was 74.6% and 85.6% (P=0.07), respectively. Among the low-risk patients, there were no obvious differences in RI, NRM, LFS, and OS between the 2 groups. For the intermediate-risk patients, 1-year NRM and OS were not significantly different, 1-year RI was 31.6% and 8.8% (P < 0.01), and 1-year LFS was 68.4% and 85.3% (P=0.02), respectively. Furthermore, the intermediate-risk patients who received MSD (HLA-matched sibling donor) PB-HCT had higher LFS than the autologous group (90.5% vs 68.4%, P < 0.01), while the LFS of the patients undergoing haploid-identical PB-HCT was not statistically different from autologous PB-HCT. Conclusion Autologous and allogeneic PB-HCT can result in a similar effect in the low-risk AML patients at the CR1 stage. Moreover, allogeneic PB-HCT is more effective for intermediate-risk patients, but only for the patients undergoing MSD PB-HCT. If there is a lack of HLA-matched sibling donor, autologous PB-HCT is an effective alternative. |
| first_indexed | 2024-12-23T10:40:31Z |
| format | Article |
| id | doaj.art-d76881aaa2da444fab4b2a7e3bf87a36 |
| institution | Directory Open Access Journal |
| issn | 1000-5404 |
| language | zho |
| last_indexed | 2024-12-23T10:40:31Z |
| publishDate | 2020-09-01 |
| publisher | Editorial Office of Journal of Third Military Medical University |
| record_format | Article |
| series | Di-san junyi daxue xuebao |
| spelling | doaj.art-d76881aaa2da444fab4b2a7e3bf87a362022-12-21T17:50:11ZzhoEditorial Office of Journal of Third Military Medical UniversityDi-san junyi daxue xuebao1000-54042020-09-0142171717172310.16016/j.1000-5404.202005132Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remissionXIAO Han0WANG Xin1LUO Xiaohua2XIAO Qing3ZHANG Hongbin4TANG Xiaoqiong5LIU Lin6Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China ] Objective To compare the efficacy of autologous and allogeneic peripheral blood hematopoietic stem cell transplantation (PB-HCT) for non-high-risk acute myeloid leukemia (AML) patients having achieved first complete remission (CR1). Methods A total of 73 patients with CR1 stage AML (non-high risk) who underwent PB-HCT in our department from January 2012 to June 2019 were enrolled in this study, and they were 49 patients receiving allogeneic PB-HCT and 24 getting autologous PB-HCT. The time of hematopoietic reconstruction, required transfusion volume, the number times of early infections, 1-year cumulative relapse incidence (RI) and non-relapse mortality (NRM), 1-year overall survival (OS) and leukemia-free survival (LFS) were compared between the 2 groups. Results There were no significant differences in hematopoietic reconstruction time, required transfusion volume and the number times of early infections between the 2 groups. As for the autologous PB-HCT group and allogeneic PB-HCT group, 1-year RI was 25.4% and 6.2% (P < 0.01); 1-year NRM was 0.0% and 8.3% (P=0.15); 1-year OS was 95.8% and 89.5% (P=0.80); and 1-year LFS was 74.6% and 85.6% (P=0.07), respectively. Among the low-risk patients, there were no obvious differences in RI, NRM, LFS, and OS between the 2 groups. For the intermediate-risk patients, 1-year NRM and OS were not significantly different, 1-year RI was 31.6% and 8.8% (P < 0.01), and 1-year LFS was 68.4% and 85.3% (P=0.02), respectively. Furthermore, the intermediate-risk patients who received MSD (HLA-matched sibling donor) PB-HCT had higher LFS than the autologous group (90.5% vs 68.4%, P < 0.01), while the LFS of the patients undergoing haploid-identical PB-HCT was not statistically different from autologous PB-HCT. Conclusion Autologous and allogeneic PB-HCT can result in a similar effect in the low-risk AML patients at the CR1 stage. Moreover, allogeneic PB-HCT is more effective for intermediate-risk patients, but only for the patients undergoing MSD PB-HCT. If there is a lack of HLA-matched sibling donor, autologous PB-HCT is an effective alternative.http://aammt.tmmu.edu.cn/Upload/rhtml/202005132.htmacute myeloid leukemiafirst complete remissionautologous transplantationallografts transplantation |
| spellingShingle | XIAO Han WANG Xin LUO Xiaohua XIAO Qing ZHANG Hongbin TANG Xiaoqiong LIU Lin Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission Di-san junyi daxue xuebao acute myeloid leukemia first complete remission autologous transplantation allografts transplantation |
| title | Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission |
| title_full | Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission |
| title_fullStr | Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission |
| title_full_unstemmed | Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission |
| title_short | Efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non-high-risk acute myeloid leukemia patients in first complete remission |
| title_sort | efficacy of autologous versus allogeneic peripheral blood hematopoietic stem cell transplantation in non high risk acute myeloid leukemia patients in first complete remission |
| topic | acute myeloid leukemia first complete remission autologous transplantation allografts transplantation |
| url | http://aammt.tmmu.edu.cn/Upload/rhtml/202005132.htm |
| work_keys_str_mv | AT xiaohan efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT wangxin efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT luoxiaohua efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT xiaoqing efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT zhanghongbin efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT tangxiaoqiong efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission AT liulin efficacyofautologousversusallogeneicperipheralbloodhematopoieticstemcelltransplantationinnonhighriskacutemyeloidleukemiapatientsinfirstcompleteremission |